A post-hoc analysis comparing data from the SYST-EUR trial and the PROGRESS trial suggests that calcium-channel blockers may have neuroprotective anti-degenerative action in addition to their blood-pressure lowering action.
The research was presented here July 23 at the 8th International Conference on Alzheimer’s Disease and Related Disorders, by Françoise Forette, MD, from Broca Hospital, University of Paris in Paris, France.
SYST-EUR (Systolic Hypertension in Europe) tested the calcium-antagonist nitrendipine, the only drug demonstrating a reduction in both Alzheimer-type and vascular dementia. Treatments consisted of nitrendipine (10-40 mg/day) with the possible addition of enalapril
(5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or a matching placebo.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!